🔗 Share this article

Government ministers and leading parliamentarians have raised concerns that the United Kingdom's negotiated accords with Donald Trump are "lacking a solid foundation." This comes after revelations that a much-touted deal on pharmaceutical tariffs, which promises zero tariffs in exchange for the NHS paying more, lacks any formal legal text beyond limited headline terms outlined by government press releases.

Lacking Legal Footing

The arrangement concerning medicines, described as a "generational" achievement, remains an "agreement in principle" without detailed provisions. Critics have noted that the official announcements from the UK and US governments describe the deal in markedly contrasting terms. The British version celebrates securing "zero per cent tariffs" as a singular success, while the American announcement highlights the agreement for the NHS to pay 25% more for new medications.

"There is a serious risk that the UK government has promised concessions to raise drug prices in return for little more than a pledge from President Trump," said David Henig, a trade policy analyst. "It is documented he has a tendency for not following through on agreements."

Wider Concerns Amidst a Suspended Agreement

Worries have been heightened by Washington's recent decision to pause the £31bn "tech prosperity deal", which was previously heralded as "a huge leap forward" in the bilateral relationship. The US claimed a failure to advance from the UK on reducing other tariffs as the reason for the pause.

In a separate development, concessions agreed to for British farmers as part of an initial accord have still not been formally ratified by the US, despite a looming January deadline. "Our understanding is that the US has not finalized the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Private Ministerial Concerns

In confidential discussions, ministers have expressed concerns that the government's US-UK accords are flimsy and unreliable. One minister reportedly said the series of agreements as "resting on shaky ground," while another framed the situation as the "current reality" in the transatlantic relationship, marked by "additional layers of volatility and unpredictability."

Layla Moran, a senior MP on the health committee, stated: "The only thing more surprising than the administration's tactics is the UK government's naive belief that his administration is a reliable partner. The NHS is not a bargaining chip."

Official Reassurances and Concrete Outcomes

Officials have attempted to minimize the possibility of the US reneging on the pharmaceuticals deal. One source indicated the US pharmaceutical industry itself had been advocating for the agreement, seeking certainty on imports and pricing, making it of tangible value than the paused tech deal.

Officials concede that unpredictability is a feature of dealing with the current US leadership. However, they argue that the UK has achieved real benefits for businesses, such as lower steel tariffs compared to other nations. "The fact we have 25% steel tariffs, which is lower than the rate for the rest of the world, is not flimsy," one official said.

However, issues have emerged in implementing the broader trade deal. Promised quotas on beef exports have yet to be finalized, and the pledge to "eliminate duties on UK metals" has remains unmet, with tariffs fixed at 25%.

Looking ahead, the two sides have planned to recommence talks on the suspended digital agreement in January, following what were described as "constructive" meetings between UK and US officials in Washington.